Leadership Overview
Regeneron has 6 executives leading key functions including strategy, science, operations, human resources, and regulatory affairs.
Driven by scientific innovation, Regeneron is dedicated to discovering, developing, and commercializing life-changing medicines for serious diseases, leveraging advanced science and proprietary technologies to address unmet medical needs globally.
Driven by scientific innovation, Regeneron is dedicated to discovering, developing, and commercializing life-changing medicines for serious diseases, leveraging advanced science and proprietary technologies to address unmet medical needs globally.
Leadership Roles at Regeneron
Leonard Schleifer - Board co-Chair, President & Chief Executive Officer
Leonard Schleifer, the Board co-Chair, President & Chief Executive Officer at Regeneron, directs the company's overarching strategy and commercialization efforts. Schleifer guides the organization's mission to discover, develop, and bring to market innovative medicines for serious diseases. This leadership role involves setting the strategic vision for Regeneron's pipeline and ensuring alignment across all business units to achieve market success. By focusing on advanced science and proprietary technologies, Schleifer drives the company's commitment to creating life-changing treatments. The Chief Executive Officer's responsibilities include fostering a culture of innovation and operational excellence, crucial for addressing complex health challenges in areas like cancer, eye diseases, and inflammatory disorders. Leonard Schleifer's executive oversight ensures that Regeneron maintains its position at the forefront of biotechnology, translating scientific breakthroughs into tangible patient benefits and sustained market impact.
Leonard Schleifer - Co-Chair, President & Chief Executive Officer
Leonard Schleifer, the Co-Chair, President & Chief Executive Officer at Regeneron, spearheads the company's strategic direction and operational execution. Schleifer's leadership ensures the effective translation of Regeneron's scientific discoveries into commercially viable treatments for severe illnesses. This executive position involves overseeing all aspects of the business, from research and development to market access, driving the company's commitment to innovation. The Chief Executive Officer's focus remains on advancing Regeneron's proprietary technologies to tackle conditions such as cancer, eye diseases, and rare disorders. By championing a forward-thinking approach, Leonard Schleifer cultivates an environment where scientific rigor meets commercial acumen, ultimately aiming to deliver transformative therapies to patients worldwide and solidify Regeneron's impact in the biotechnology sector.
George Yancopoulos - Co-Founder, Board Co-Chair, President & Chief Scientific Officer
George Yancopoulos, the Co-Founder, Board Co-Chair, President & Chief Scientific Officer at Regeneron, leads the company's pioneering scientific research and development efforts. Yancopoulos directs the discovery and advancement of novel therapeutic approaches, driving Regeneron's commitment to creating life-changing medicines for severe and rare diseases. This executive role is central to translating cutting-edge science and proprietary technologies into tangible treatments for conditions such as cancer, eye diseases, and inflammatory disorders. The Chief Scientific Officer's vision guides the research pipeline, ensuring a continuous flow of innovative therapies. Under George Yancopoulos's scientific leadership, Regeneron consistently pushes the boundaries of biotechnology, fostering an environment of discovery that aims to profoundly impact global health and patient outcomes.
Kim Brenner - Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality
Kim Brenner, the Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality at Regeneron, manages critical operational strategies and ensures the highest standards in regulatory compliance, patient safety, and quality assurance. Brenner's role involves developing and implementing strategic initiatives that enhance operational efficiency across the organization, directly supporting the company's mission to deliver life-changing medicines. This executive leadership position requires a deep understanding of complex regulatory landscapes and a commitment to safeguarding patient well-being throughout the drug development and commercialization lifecycle. Overseeing patient safety and quality functions, Kim Brenner ensures that Regeneron's treatments meet stringent global standards. The executive VP's strategic input is vital for aligning operational processes with Regeneron's scientific advancements and market objectives, reinforcing the company's dedication to ethical and effective healthcare solutions.
Erin Rohr - Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources
Erin Rohr, the Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources at Regeneron, drives human capital strategies that support the company's growth and innovation in biotechnology. Rohr's responsibilities encompass aligning HR initiatives with Regeneron's core mission of developing transformative medicines for serious diseases. This executive role involves partnering with leadership to foster a high-performance culture, attract and retain top scientific and operational talent, and ensure robust employee development programs. The Vice President of Human Resources plays a key part in shaping the employee experience, crucial for maintaining Regeneron's competitive edge in research and development. Erin Rohr's strategic HR insights contribute directly to operational effectiveness and the overall success of Regeneron's efforts to bring life-changing treatments to patients globally.
Wrechelle Nantes - Executive Assistant To the Chief Human Resources Officer
Wrechelle Nantes, the Executive Assistant To the Chief Human Resources Officer at Regeneron, provides essential support to the human resources leadership, facilitating the smooth execution of HR strategies and operations. Nantes's role is integral to ensuring that the human resources department effectively supports Regeneron's mission of developing innovative medicines for serious diseases. This position involves managing complex administrative functions, coordinating executive communications, and supporting initiatives aimed at talent acquisition, employee engagement, and organizational development. The executive assistant's meticulous attention to detail and organizational skills are critical for maintaining efficiency within the HR function. Wrechelle Nantes's contributions directly enable the Chief Human Resources Officer to focus on strategic priorities, thereby reinforcing Regeneron's commitment to scientific advancement and patient well-being.
Explore Leadership Teams in Manufacturing
Founded in 1989, Macleods Pharmaceutical develops and manufactures generic pharmaceuticals. The Company offers tablets, drugs, syrup, and other related products. The company is headquartered in Mumbai, Maharashtra, India.
Company Leadership AP
BP
AM
AS
PCI Pharma Services is an integrated full service provider to companies in the global healthcare industry. They offer services including analytical services, formulation development, clinical trial supply, commercial manufacturing and packaging, QP services, supply chain management, storage, and distribution. They are headquartered in Philadelphia, Pennsylvania with locations in the United States and Europe.
Company Leadership HL
ED
LR
BK
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, were rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. Today, Amneal is much more than generics. A series of strategic investments over the years has bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. We have also invested substantially in our people through leadership development and employee well-being programs. Together, these advancements have accelerated our ability to deliver innovation, more complex products and broadened portfolios in new categories and geographies. Two decades after our founding, Amneal is better positioned than ever to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrows health challenges. We are Amneal and We make healthy possible.
Company Leadership
HK
Parabolic Drugs Limited is a vertically integrated, research-based pharmaceutical manufacturer and exporter, specializing in the production of over 50 active pharmaceutical ingredients (APIs) and intermediates across various therapeutic segments. The company operates four large-scale facilities, including three state-of-the-art manufacturing plants and a custom synthesis and R&D center. With a focus on backward and forward integration, world-class infrastructure, and strong R&D capabilities, Parabolic Drugs is committed to delivering high-quality products. Their diverse product portfolio is supported by intellectual property rights, including Drug Master Files (DMFs) and patents for novel processes.
Company Leadership AN
AJ
VG
YB
Frequently Asked Questions Regarding Regeneron Top Executives and Leadership Team
